BACKGROUND AND PURPOSE: Ischemia-reperfusion injury plays an important role in the development of primary allograft failure after heart transplantation. Inhibition of the Na+/H+ exchanger is one of the most promising therapeutic strategies for treating ischemia-reperfusion injury. Here we have characterized the cardioprotective efficacy of zoniporide and the underlying mechanisms in a model of myocardial preservation using rat isolated working hearts. EXPERIMENTAL APPROACH: Rat isolated hearts subjected to 6 h hypothermic (1-4°C) storage followed by 45 min reperfusion at 37°C were treated with zoniporide at different concentrations and timing. Recovery of cardiac function, levels of total and phosphorylated protein kinase B, extracellular signal-regulated kinase 1/2, glycogen synthase kinase-3β and STAT3 as well as cleaved caspase 3 were measured at the end of reperfusion. Lactate dehydrogenase release into coronary effluent before and post-storage was also measured. KEY RESULTS: Zoniporide concentration-dependently improved recovery of cardiac function after reperfusion. The functional recovery induced by zoniporide was accompanied by up-regulation of p-extracellular signal-regulated kinase 1/2 and p-STAT3, and by reduction in lactate dehydrogenase release and cleaved caspase 3. There were no significant differences in any of the above indices when zoniporide was administered before, during or after ischemia. The STAT3 inhibitor, stattic, abolished zoniporide-induced improvements in functional recovery and up-regulation of p-STAT3 after reperfusion. CONCLUSIONS AND IMPLICATIONS: Zoniporide is a potent cardioprotective agent and activation of STAT3 plays a critical role in the cardioprotective action of zoniporide. This agent shows promise as a supplement to storage solutions to improve preservation of donor hearts.
BACKGROUND AND PURPOSE:Ischemia-reperfusion injury plays an important role in the development of primary allograft failure after heart transplantation. Inhibition of the Na+/H+ exchanger is one of the most promising therapeutic strategies for treating ischemia-reperfusion injury. Here we have characterized the cardioprotective efficacy of zoniporide and the underlying mechanisms in a model of myocardial preservation using rat isolated working hearts. EXPERIMENTAL APPROACH: Rat isolated hearts subjected to 6 h hypothermic (1-4°C) storage followed by 45 min reperfusion at 37°C were treated with zoniporide at different concentrations and timing. Recovery of cardiac function, levels of total and phosphorylated protein kinase B, extracellular signal-regulated kinase 1/2, glycogen synthase kinase-3β and STAT3 as well as cleaved caspase 3 were measured at the end of reperfusion. Lactate dehydrogenase release into coronary effluent before and post-storage was also measured. KEY RESULTS:Zoniporide concentration-dependently improved recovery of cardiac function after reperfusion. The functional recovery induced by zoniporide was accompanied by up-regulation of p-extracellular signal-regulated kinase 1/2 and p-STAT3, and by reduction in lactate dehydrogenase release and cleaved caspase 3. There were no significant differences in any of the above indices when zoniporide was administered before, during or after ischemia. The STAT3 inhibitor, stattic, abolished zoniporide-induced improvements in functional recovery and up-regulation of p-STAT3 after reperfusion. CONCLUSIONS AND IMPLICATIONS: Zoniporide is a potent cardioprotective agent and activation of STAT3 plays a critical role in the cardioprotective action of zoniporide. This agent shows promise as a supplement to storage solutions to improve preservation of donor hearts.
Authors: Jonathan Rhys David Cropper; Mark Hicks; Jonathon Bruce Ryan; Peter Simon Macdonald Journal: J Heart Lung Transplant Date: 2003-08 Impact factor: 10.247
Authors: Karen L Wu; Shenaz Khan; Sujata Lakhe-Reddy; George Jarad; Amitava Mukherjee; Carlos A Obejero-Paz; Martha Konieczkowski; John R Sedor; Jeffrey R Schelling Journal: J Biol Chem Date: 2004-04-19 Impact factor: 5.157
Authors: P Menasché; J L Termignon; F Pradier; C Grousset; C Mouas; G Alberici; M Weiss; A Piwnica; G Bloch Journal: Eur J Cardiothorac Surg Date: 1994 Impact factor: 4.191
Authors: John M Trahanas; Lucas J Witer; Fares Alghanem; Benjamin S Bryner; Amit Iyengar; Jacob R Hirschl; Mark J Hoenerhoff; Joseph A Potkay; Robert H Bartlett; Alvaro Rojas-Pena; Gabe E Owens; Martin L Bocks Journal: ASAIO J Date: 2016 Jul-Aug Impact factor: 2.872
Authors: Javid Fatullayev; Mostafa Samak; Anton Sabashnikov; Alexander Weymann; Prashant N Mohite; Diana García-Sáez; Nikhil P Patil; Pascal M Dohmen; Aron-Frederik Popov; Andre R Simon; Mohamed Zeriouh Journal: Med Sci Monit Basic Res Date: 2015-07-15
Authors: Jeanette E Villanueva; Ling Gao; Hong C Chew; Mark Hicks; Aoife Doyle; Min Ru Qui; Kumud K Dhital; Peter S Macdonald; Andrew Jabbour Journal: PLoS One Date: 2018-10-12 Impact factor: 3.240
Authors: Jeanette E Villanueva; Hong C Chew; Ling Gao; Aoife Doyle; Sarah E Scheuer; Mark Hicks; Andrew Jabbour; Kumud K Dhital; Peter S Macdonald Journal: Transplant Direct Date: 2021-05-18
Authors: Christopher W White; Simon J Messer; Stephen R Large; Jennifer Conway; Daniel H Kim; Demetrios J Kutsogiannis; Jayan Nagendran; Darren H Freed Journal: Front Cardiovasc Med Date: 2018-02-13